Second Announcement:

We would like to bring to your attention the 2nd Introductory Training Course on

'Pharmacokinetics and Pharmacodynamics of Protein Therapeutics - Concepts and 
Hands-On Modeling and Simulation'

The course will be held at the facilities of the University of Tennessee Health 
Science Center in Memphis, TN, USA, on April 16-20, 2012.

The 5-day course will introduce participants to basic principles in the 
pharmacokinetic and pharmacodynamic evaluation of novel protein therapeutics 
and provide opportunities for hands-on PK and PK/PD modeling and simulation 
examples relevant for protein drugs. Topics include target-mediated drug 
disposition, tissue and tumor penetration, interspecies scaling, first-in-human 
dose selection, immunogenicity, model-based drug development, disease 
progression modeling, and drug-drug interactions. The target audience comprises 
pharmaceutical scientists from industry, academia and regulatory agencies with 
basic knowledge in PK and PKPD that had only limited exposure to the challenges 
associated with developing protein therapeutics and that would like to receive 
a comprehensive first overview or refresher on the PK and PKPD of this class of 
compounds.

For more detailed information on the course program and registration, please 
visit

www.PKPDofProteinTherapeutics.com<http://www.PKPDofProteinTherapeutics.com>

We hope you will join us in April in Memphis!

The Course Directors
Bernd Meibohm, University of Tennessee & Johan Gabrielsson, Swedish University 
of Agricultural Sciences


***********************************************
Bernd Meibohm, PhD, FCP
Associate Dean for Graduate Programs & Research
Professor of Pharmaceutical Sciences
College of Pharmacy
University of Tennessee Health Science Center
881 Madison Avenue, Rm. 444
Memphis, TN 38163, U.S.A.
Phone (901) 448-1206
Fax (901) 448-6940
Email [email protected]<mailto:[email protected]>
************************************************
For more information:
http://www.uthsc.edu/pharmacy/pharmsci/faculty/bmeibohm/

Reply via email to